Literature DB >> 22506582

Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.

B M Nørgård1, J Nielsen, N Qvist, K O Gradel, O B S de Muckadell, J Kjeldsen.   

Abstract

BACKGROUND: It is still controversial whether pre-operative anti-tumour necrosis factor-alpha (anti-TNF-α) agents increase post-operative complications in patients with ulcerative colitis (UC). AIM: In a nationwide Danish cohort of patients with UC, we aimed to examine the impact of pre-operative use of anti-TNF-α agents on post-operative adverse outcomes after colectomy for UC. Outcomes (within 30 and 60 days after surgery) were reoperation, anastomosis leakage, intra-abdominal abscess, bacteremia and death.
METHODS: Based on the Danish National Patient Registry we identified all UC patients, aged ≥15 years, having their first surgery for UC in the period of 1 January 2003-31 December 2010 (n = 1226). Patients were classified according to use of anti-TNF-α agents within 12 weeks before surgery or not. Outcome data were obtained from Danish registries. Logistic regression analyses were used to estimate adjusted risks [with 95% confidence intervals (CI)] of post-operative outcomes among patients treated with anti-TNF-α agents, relative to those not treated.
RESULTS: A total of 199 UC patients were exposed to anti-TNF-α agents within 12 weeks before colectomy, and 1027 were not. Among exposed, the adjusted odds ratio of reoperation and anastomosis leakage within 30 days after colectomy was 1.07 (95% CI: 0.71-1.59) and 0.52 (95% CI: 0.06-4.11) respectively. No deaths, cases of abscess drainage or bacteremia occurred among exposed within 30 days. Furthermore, no increased relative risks were found within 60 days after colectomy.
CONCLUSIONS: Based on nationwide data on UC patients having colectomies, pre-operative use of anti-TNF-α agents did not increase the risk of post-operative complications.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22506582     DOI: 10.1111/j.1365-2036.2012.05099.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

Review 2.  [Refractory inflammatory bowel disease: surgical challenges].

Authors:  H J Buhr; A J Kroesen
Journal:  Chirurg       Date:  2013-11       Impact factor: 0.955

3.  GM6001 Increases Anastomotic Leakage following Colonic Obstruction Possibly by Impeding Epithelialization.

Authors:  Martin Rehn; Peter-Martin Krarup; Lise H Christensen; Jakob B Seidelin; Magnus S Ågren; Ingvar Syk
Journal:  Surg Infect (Larchmt)       Date:  2015-07-14       Impact factor: 2.150

4.  Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis.

Authors:  YuJie Qiu; ZiCheng Zheng; Gang Liu; XinYu Zhao; AnQi He
Journal:  United European Gastroenterol J       Date:  2019-09-30       Impact factor: 4.623

5.  Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience.

Authors:  Chaya Shwaartz; Adam C Fields; Maximiliano Sobrero; Brian D Cohen; Celia M Divino
Journal:  J Gastrointest Surg       Date:  2016-07-12       Impact factor: 3.452

6.  Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.

Authors:  Ryan Nelson; Chuanhong Liao; Alessandro Fichera; David T Rubin; Joel Pekow
Journal:  Inflamm Bowel Dis       Date:  2014-01       Impact factor: 5.325

Review 7.  Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis.

Authors:  Christopher Alexakis; Richard Cg Pollok
Journal:  World J Gastrointest Surg       Date:  2015-12-27

8.  Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis.

Authors:  Audrey S Kulaylat; Afif N Kulaylat; Eric W Schaefer; Andrew Tinsley; Emmanuelle Williams; Walter Koltun; Christopher S Hollenbeak; Evangelos Messaris
Journal:  JAMA Surg       Date:  2017-08-16       Impact factor: 14.766

Review 9.  Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis.

Authors:  Florian Kuehn; Richard A Hodin
Journal:  Visc Med       Date:  2018-10-31

10.  Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.

Authors:  Cindy Cy Law; Conor Bell; Deborah Koh; Yueyang Bao; Vipul Jairath; Neeraj Narula
Journal:  Cochrane Database Syst Rev       Date:  2020-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.